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Abstract 
 
The part of the innate immune system that communicates and effectively primes the 
adaptive immune system was termed “complement” by Ehrlich to reflect its 
complementarity to antibodies having previously been described as “alexine” (i.e 
protective component of serum) by Buchner and Bordet.   It has been established 
that complement is not solely produced systemically but may have origin in different 
tissues where it can influence organ specific functions that may affect the outcome of 
transplanted organs.  This review looks at the role of complement in particular to 
kidney transplantation.  We look at current literature to determine whether blockade 
of the peripheral or central compartments of complement production may prevent 
ischaemic reperfusion injury or rejection in the transplanted organ.   
 
We also review new therapeutics that have been developed to inhibit components of 
the complement cascade with varying degrees of success leading to an increase in 
our understanding of the multiple triggers of this complex system.  In addition, we 
consider whether biomarkers in this field are effective markers of disease or 
treatment. 
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1. Introduction 
1.1 What is complement? 
The complement system was first recognised as a fundamental part of the innate 
immune system in the late 1890s. It initiates and maintains host defence by 
combining recognition molecules, proteolytic enzymes, receptors and foreign or 
altered internal products.  The complement system comprises of 35-40 components 
and regulators that are soluble or membrane bound and catalyse the breakdown of 
converting enzyme complexes or convertases that lead to the formation of 
membrane attack complex (C5b, C6, C7, C8 and C9 (C5b-C9)).  Activation of the 
complement cascade has been described to use three pathways; the classical, lectin 
and alternative pathways (Fig 1). The classical pathway is triggered by antigen-
antibody immune complexes arising from immune surveillance molecules (e.g. IgG, 
IgM, C-reactive protein) leading to activation of C4, C2 and C3.  The lectin pathway 
is initiated by collectins (e.g. mannose binding lectin, MBL) and ficolins, which bind to 
carbohydrate ligands on the surface of pathogens.  This subsequently leads to the 
formation of C4b, C2a - the C3 convertase complex similar to the classical pathway.  
In contrast, the alternative pathway is activated by either spontaneous hydrolysis of 
C3 or by C3b binding to the activated surface thus amplifying the cascade, using 
Factors B, D and P to form the alternative C3 convertase C3bBb.   
 
Initiation of the complement cascade results in the deposition of C3 onto the 
activating surface.  Cleavage of C3 forms C3a and C3b with the latter triggering 
formation of C5 convertase.  C5 is cleaved leading to formation of C5b-C9.  The 
anaphylatoxins (C3a and C5a) are potent pro-inflammatory molecules that are 
chemoattractant and activate leucocytes via C3aR and CD88 (C5aR1).  Opsonins 
(C3b, inactive C3b (iC3b) and degradation product C3d) remain covalently bound to 
target surfaces facilitating transport and removal of the targeted cells or immune 
complexes.  Formation of C5b-9 in the targeted cell membrane results in direct lysis 
of the pathogen causing cell activation, injury and death [1].  The complement 
system is regulated by a number of inhibitors and regulators to prevent local 
destruction of tissues.  CD35 (CR1), CD46 (MCP), CD55 (DAF), C4BP (C4b-binding 
protein) and Factor H are all members of the same family of complement regulatory 
proteins that have similar structures with varying number of subunits that are 
encoded on chromosome 1 and inhibit the functions of the converting enzyme 
complexes that cleave C3 and C5. In addition, CD59 inhibits the formation of C5b-
C9.  Complement regulators have a number of functions that are described in Table 
1. Dysregulation of the complement regulators has increasingly been described in a 
number of diseases such as age-related macular degeneration, systemic lupus 
erythematosus (SLE), spinal cord injuries, atypical haemolytic uraemic syndrome 
(aHUS), arthritis, autoimmune heart disease and paroxysmal nocturnal 
hemoglobinuria) [2-7]. Complement has also been described to be important in 
priming the adaptive immune system whereby C3a and C5a released by local 
complement activation act as cofactors for stimulation of antigen presentation whilst 
enhancing activation of naïve alloreactive T cells [8-12]. 
 
1.2 Peripheral and central complement production 
An intra and extravascular pool of complement has previously been described 
whereby hepatic synthesis mainly maintains the intravascular pool.  In contrast the 
extravascular pool arises from peripheral or local tissue cellular activity from tissue-
resident and migratory cells such as antigen presenting cells (APCs), T cells and 
tubuloepithelial cells in the kidney [13, 14].  It has been argued that C3 could be 
maintained in the central compartment due to its 180kDa size; however it is ill-
understood as to whether retention of this large complement molecule in the central 
compartment is due to size alone [15, 16].  Other circulating complement factors 
including C2, C4 and Factor B can similarly be generated in tissue-resident cells.  
Animal studies have previously described the important role of central and peripheral 
pools of C3 with uncontrolled locally produced complement resulting in effective and 
rapid complement mediated tissue damage [15].  C3 arising from the transplanted 
kidney following an ischaemic insult has been described to be dependent on the cold 
ischaemic time prior to surgery with deposited C3 levels peaking approximately 48 
hours following the surgery, though in patients it has been reported that complement 
activation may begin in the organ donor [17, 18].  This results in significant damage 
to the tubuloepithelial cells that are susceptible to hypoxic damage.  Tubuloepithelial 
cells are the main source of local complement in the kidney, however all cellular 
compartments of the kidney are able to synthesise complement, based on in vivo 
and ex vivo analysis [19].  Improving our understanding in this area and of the inter-
individual variations that confer disease susceptibility will allow us to deliver targeted 
specific personalised medicine to prevent the decline in allograft function [20].  The 
remainder of this review will focus on the role of complement in kidney 
transplantation, which is the most common type of solid-organ transplantation 
performed. 
 
2. Kidney transplantation 
The complement system has provided a natural barrier to xenotransplantation for 
many years, with damage to pig organs arising from exposure to human serum [21, 
22]. Studies in allotransplantation have also highlighted the importance of 
complement in alloantibody-mediated rejection. Subsequently it became apparent 
that peripheral complement also plays a central role determining how the donor 
organ responds to the stress of transplantation [23]. Further work has identified how 
alloimmune priming and cell-mediated rejection are complement-dependent. In this 
review, we shall focus on the role of complement in several of these functions that 
are relevant to current clinical practice. 
 
2.1 Ischaemia-reperfusion injury 
Ischaemia-reperfusion (IR) injury is thought to be the main contributor to the 
development of delayed graft function (DGF).  DGF occurs in a third of all deceased 
donor organs rising to 50% in circulatory deceased donors [24].  This has led to an 
increase in reperfusion machine studies to determine whether the injury sustained 
may decrease with normothermic or hypothermic perfusion [25, 26].  IR injury arises 
from a combination of tissue hypoxia, mitochondrial damage, ATP depletion and free 
oxygen radicals on reperfusion, leading to damage of the endothelium and 
epithelium.  This induces cellular inflammation via toll-like receptors, cytokines, 
chemokines and complement.  Complement activation both initiates and propagates 
tissue damage not only in kidney transplantation but also in other major transplanted 
organs such as the heart, lung, liver and pancreas [27-32]. 
 
 
 
Figure 1. The complement cascades. 
The classical pathway is triggered by the C1 complex (C1q, C1r, C1s) binding to antibody or 
C-reactive protein on the activating surface, leading to the formation of the classical pathway 
C3 convertase from C4 and C2 (C4bC2a) and to subsequent cleavage of C3.  The lectin 
pathway is activated by collectins (e.g. Mannose binding lectin, MBL) or ficolins that detect 
carbohydrate residues, IgA or IgM on the activating surface. Complexes formed between the 
lectin molecule and MBL-associated serine proteases result in the formation of C3 convertase 
(C4bC2a), as per the classical pathway. In contrast the alternative pathway begins with direct 
binding of C3b to the activating surface after spontaneous hydrolysis of C3 or following the 
deposition of C3b by the classical or lectin pathway. In this case, C3b binds factor B followed 
by cleavage of factor B to form the alternative pathway C3 convertase (C3bBb). All three 
pathways form enzyme complexes (classical or alternative convertases) that cleave C3 into 
C3a and C3b and ultimately cleave C5 into C5a and C5b. C5b triggers the terminal pathway 
forming the membrane attack complex (C5b-C9), which creates a pore in the cells membrane 
resulting in cell lysis and death.  Specific cell surface receptors detect C3a, C5a, iC3b, C3b 
and C3d.  Complement regulators (CR) include: CD35 (CR1), CD46 (MCP), CD55 (DAF), 
C4BP (C4b-binding protein) and complement Factor H, which function by accelerating decay 
of the C3 and C5 convertases or by acting as cofactors for the proteolysis of these 
convertases by Factor I, or have both of these actions; and CD59 (Protectin), which binds C8 
and inhibits membrane attack complex formation Table 1 provides further details of CR.  
 
 
 
 
Complement-mediated injury following IR insult mainly arises from C5a and C5b-C9 
terminal pathway products.  This has been found in studies of complement deficient 
and depleted mice that are protected against reperfusion damage [30, 31, 33, 34].  
C5a acts directly on the C5a receptor on parenchymal cells, as well as stimulating 
chemotaxis and degranulation of neutrophils [35, 36].  In contrast C3a is reported to 
have a less significant role in IR injury [37]. It has been suggested that donor-kidney 
derived C3 is a more effective driver of IR injury than the systemic recipient C3 [15].  
The degree of C3b involvement in this process is presently unclear. 
 
We have previously described an increase in the synthesis of C3 in transplanted 
kidneys to be dependent on the length of cold ischaemia prior to transplantation in a 
mouse model [15]. A number of other stress-related factors such as interferon-γ 
(IFNγ), lipopolysaccharide (LPS) and IL-1 may also increase the production of 
complement generating C5a and C5b-C9 and consequent graft dysfunction.  
Complement activation on endothelial and epithelial cells in turn can upregulate or 
mediate the release of pro-inflammatory and fibrotic factors including tumour 
necrosis factor (TNF), interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1) 
and collagen causing chronic tissue damage if they remain unregulated [38-40].    
The presence of complement factors in human donor kidneys pre-transplantation 
have previously been reported with poor allograft function 3 years later [19].  The 
balance of complement production and regulation is cell dependent within the organ 
affected.  It appears that endothelial cells and myocytes are the predominant targets 
in post ischaemic heart and intestine respectively, whilst proximal tubuloepithelial 
cells regulate damage within the transplanted kidney [18, 24, 37, 38, 41, 42]. 
 
IR injury may also arise from activation of complement receptors.  This has been 
suggested from reports in brain deceased donors whose raised donor CD88 
expression on renal tubuloepithelial cells is associated with worse allograft function 
compared to living donors [43].  In addition, bone marrow chimera studies in mice 
deficient in C3aR and CD88 on renal tubuloepithelial cells or circulating leucocytes 
resulted in little IR injury in the kidney [44].  C5b-9 has also been reported to be 
detected in pre-implantation renal allograft biopsies of human deceased donors with 
none seen in live donors.  In addition, whole genome profiling has discovered a 
number of highly expressed complement genes in human donor organs with IR 
thereby supporting the important role of complement in IR injury [19, 45]. 
 
2.1.1 Complement activation pathways in IR injury 
Each complement pathway uses different triggers that respond to various pathogenic 
factors such as infection, ischaemia and hypothermia.  Initially it was thought that the 
classical pathway was involved in IR as C4 and natural IgM were shown to be 
central to IR damage in cardiac and skeletal muscle and later in intestinal tissue [41, 
46, 47].  Classical pathway activation is dependent on C1q binding to 
immunoglobulins, C-reactive protein or other tissue-adherent surveillance molecules; 
however recent studies have shown IgM to stimulate the lectin pathway directly thus 
questioning the role of the classical pathway in IR injury. 
 
IR specifically stimulates the lectin pathway where MBL binds to carbohydrate 
residues on the activating surface to trigger complement mediated damage [46, 48-
50].  MBL-associated serine proteases (MASP-1,2 and 3) are proteolytic enzymes 
that bind to collectins and ficolins to initiate complement activation.  MASP-2 is 
notable in that it is able to mediate cleavage of C3 without C4 [51].  MBL has been 
described to be internalised by renal proximal tubuloepithelial cells in organ 
reperfusion whereby they are destroyed by apoptosis in a murine model [52].  
Interestingly this cytotoxic effect is independent of complement activation and 
specific to MBL.  Studies have also reported activation of the lectin pathway via 
binding of IgM with myosin like molecules exposed in tissues with ischaemic injury 
[53].  Identifying other triggers of the lectin pathway in IR may lead to novel specific 
therapeutic targets.  A recent study demonstrates a role for collectin-11 (CL-11) in 
renal IR injury, whereby CL-11 produced by the renal tubuloepithelial cell appears to 
trigger complement activation along the basolateral tubuloepithelial surface [54].      
 
In a study looking at simultaneous kidney pancreas transplantation, low circulating 
levels of MBL were associated with good allograft outcome [55].  A different study 
associated low MBL levels with poor renal allograft function and survival in non-HLA 
sensitised patients [56].  These differences may arise from the detection assay used 
with different antibodies binding high or low-order oligomers of MBL.  High-oligomers 
of MBL have higher affinity for carbohydrates thereby stimulating the lectin pathway 
[57].  Poor graft survival has also been associated with high serum levels of ficolin-3, 
a recognition molecule that activates the lectin pathway, in a study of >500 renal 
transplant recipients [58]. 
 
The alternative pathway involves complement factor B thereby facilitating an 
increase in C3b available for deposition on cells from the above pattern recognition 
pathways.  Murine studies have shown factor B deficient mice to be protected from 
IR injury and therefore its presence may significantly amplify the amount of injury 
mediated by the complement system [59].  Human heart and kidney transplant 
biopsies have been reported to have products from the lectin and alternative 
pathway, respectively [10, 18, 60].  Complement is also known to impair vasculature 
remodelling that is required post transplantation and thus may induce or perpetuate 
the ischaemic injury on the organ [61]. 
 
2.2 Kidney Transplant Rejection 
2.2.1 Cell-mediated allograft rejection 
Products of complement can be detected in the blood, urine and organ biopsies of 
patients with cellular cardiac or kidney rejection [62-67].  The tubuloepithelial 
compartment of the kidney is the main source of local complement production during 
rejection, with infiltrating cells also contributing to the levels [65, 68].  For example, 
10% of circulating C3 found during clinical episodes of rejection have been reported 
to originate from the kidney allograft compared to the 5% found in stable kidney 
allograft function [66].  Interestingly only 1% of circulating complement detected is of 
myeloid origin following a bone marrow transplant [69].  This supports the role of 
organ produced complement detected in mouse studies, and its potential of initiating 
or sustaining local injury through these mechanisms thereby introducing novel 
therapeutic targets. 
 
Donor derived complement in murine kidney transplantation has been reported to be 
essential for acute allograft rejection [16].  Transplantation of kidneys from C3-
deficient donors resulted in an increased rejection free survival supporting a role for 
donor-derived C3 in murine transplant rejection [16].   These models illustrate how 
complement damages the renal parenchyma directly and indirectly by enhancing the 
recipient’s T cell response in a C3 dependent manner [31, 47].  A similar 
phenomenon is reported in cardiac transplants with activation of the classical and 
alternative pathways via inhibition of the complement regulator CD55 [70-72]. 
 
C3 downstream products C3a and C5a have been shown to be important in antigen 
presentation thus further stimulating T cell responses against alloantigens, inducing 
rejection [10, 14, 39, 41, 47, 53, 73, 74].  Recipient T cells are known to be primed 
within the first 24 hours following transplantation as donor APCs migrate to the 
recipient lymphoid system.  Once primed, alloreactive T cells enter the graft resulting 
in graft rejection.  Studies have reported the susceptibility of APCs to complement 
products generated through cleavage of C3 [10, 75].  In addition, APCs stimulated 
with C3a or C5a increased their ability to effectively stimulate alloreactive T cells via 
nuclear factor-ĸB (NF-ĸB) signalling [39, 41].  APCs such as macrophages and 
dendritic cells (DC) are known to produce C3 and C5 [76].  C3a/C3aR and 
C5a/CD88 upregulate and release IL-12 and IL-23 from macrophages and DC.  Co-
stimulating molecules CD80, CD86 are also increased [49, 74].  APCs deficient in 
C3aR/CD88 reduce circulating IL-12 levels and CD80, inducing weak T cell 
responses promoting graft survival.  Murine studies have shown macrophages from 
CD55 deficient mice induce stronger T cell responses and IL-12 than wild types.  
Recently the effect of donor derived APCs C3a/C5a production was also seen to 
decrease human T cell alloresponses when small interfering RNA (siRNA) 
knockdown of DC expressed C3 in human cultures.  Following knockdown of DC 
expressed CD55, T cell proliferation was observed as increased levels of C3a/C5a 
were detected supporting donor APCs as an important source of complement [77]. 
 
In addition to APC, T cells express a number of complement receptors such as 
C3aR and possibly CD88 that may be activated against major histocompatibility 
antigens directly by signals from soluble and membrane bound products of 
complement [12, 38].  CD88 signalling has also been reported to be beneficial in 
altering the balance of the death receptor CD95 (FAS) and the anti-apoptotic factor B 
cell lymphoma 2 (BCL-2) thus improving T cell survival by promoting T cell 
proliferation and inhibiting apoptosis [38].  Proinflammatory cytokines can stimulate 
endothelial cells to produce C5a with activation of the alternative pathway.  This 
locally synthesised C5a induces proliferation and expansion of CD8+Tcells [53].  
CD4+Tcells are able to interact with tubuloepithelial cells via interactions between 
C3b and CD35 leading to enhanced CD4+Tcell alloreactivity [78].  Complement 
activation has also shown CD4+Tcells help CD8+Tcell expansion during renal 
allograft rejection [72]. 
 
Tregs have long been reported to have a central role in the development and 
maintenance of allograft tolerance [79, 80].  Complement is known to regulate Tregs 
via signalling through C3aR and CD88 resulting in inhibition of Treg function [81].  In 
this murine study C3aR/CD88 antagonists enhanced induced Treg (iTreg) activity 
promoting allogenic skin graft survival.  CD88 antagonist has also been reported to 
enhance human iTreg production and stability in murine recipients of human 
peripheral blood mononuclear cells [82].  These complement receptors may 
therefore be novel targets for blocking complement signalling in order to facilitate 
iTreg mediated tolerance in allografts. Complement has thus been likened to a 
double-edged blade that enhances T-cell mediated immunity but yet is required for T 
cell tolerance induction, in different model systems.  The inhibition of complement 
currently presents a challenge for predicting and inducing the desired effect on 
Tregs. 
 
2.2.2 Antibody mediated rejection (AMR) 
Both the production and effect of alloantibodies on tissue injury in transplantation are 
dependent on complement.  This is increasingly important, as the development of 
HLA antibodies formed post transplantation have been correlated with poor allograft 
function.  C3 has long been described as an opsonin that effectively maintains 
antigens for B cell stimulation via receptor CR2 for antibody production [83-85].  
Complement deficient mice undergoing bone marrow transplantation have 
subsequently regained their ability to produce antibodies via donor C3 producing 
monocytes repopulating the central lymphoid system of these animals [86, 87].  It 
has been reported that complement deficient mice are unable to produce high affinity 
IgG responses against MHC antigens in skin grafts.  They lack C4 dependent 
cleavage of C3, suggesting the classical or lectin pathway affects the anti-donor IgG 
response [88].  
 
Donor specific antibodies (DSAs) are antibodies that in vitro have the ability to 
activate complement (i.e. bind C1q).  DSAs that bind donor HLA molecules may be 
complement fixing resulting in complement activation via the classical pathway and 
C4 deposition on the graft with subsequent split produce C4d.  In contrast, non-
complement fixing DSAs have not been associated with renal transplant decline [89].  
C4d has long been described as a feature of AMR, however C4d independent AMR 
has since been described and thus a recognised effort is also being made to prevent 
alloantibody production to prevent AMR [90].  B cell depletion using Rituximab (anti 
CD20 monoclonal antibody) has been reported to decrease AMR and improve graft 
survival [91].  A combined approach of B cell depletion and complement suppression 
could prove to be effective in promoting long term graft survival. 
 
2.2.3 Chronic AMR (CAMR) 
The development of new immunosuppressive therapies has decreased the incidence 
of cellular rejection and acute AMR making chronic AMR a predominant cause of 
late allograft loss [92, 93].  The presence of HLA-DSA is linked to lower levels of 
functioning grafts from deceased donors, with 70% functioning at 5 years compared 
with 80-90% graft survival in those with no antibodies.  The typical histological 
feature of CAMR in the kidney is described as transplant glomerulopathy (TG), 
where its presence has been associated with preformed DSAs present at 
transplantation [94].  Currently it is thought CAMR arises from an initial injury 
involving DSAs and complement activation whose chemotaxic effects result in 
inflammatory cell infiltration.  It is postulated that TG is the consequence of 
continuous peritubular glomerulitis and capillaritis or that low levels of DSA and 
complement are present in the graft, but current assays are unable to measure them 
[95].  There are also reports of endothelial cell and smooth muscle cell activation by 
DSAs alone in in-vitro studies thereby suggesting complement-independent 
mechanisms may contribute to chronic endothelial cell damage [96, 97].  The 
treatment and prevention of CAMR therefore continues to be a challenge. 
 
2.3 Negative regulation of the immune system by complement - a role in 
tolerance? 
Normally the C3b receptor known as CD46 modulates human CD4+T cells towards 
an immunosuppressive phenotype producing IL-10.  In autoimmune diseases this 
mechanism is lacking and may explain how complement induced T regulatory type 1 
cells (TR1 cells) may modulate T cell-mediated immunity against self-antigens [98].  
People with complete complement C3 deficiency have low numbers of TR1 cells with 
impaired CD46 T cells.  Complement activation has also been found to play a role in 
graft tolerance by inducing non-responsive T cells [99]. 
 
Induction of graft tolerance has been described in murine studies.  Skin grafting 
performed on male to female mice initiates a T cell response to minor 
histocompatibility antigen H-Y resulting in rejection.  Rejection was seen to be more 
aggressive in female C3 deficient mice.  Induction of tolerance occurred following 
nasal immunization of the mice with an H-Y peptide whose reaction is also 
dependent on C3 thereby suggesting that complement activation is necessary to 
induce nonresponsive H-Y specific T cells [99].  C3 appears to be important in the 
development of inhibitory T cells that promote tolerance against alloantigens 
however this effect seems to be limited to minor histocompatibility mismatches 
between the donor and recipient.  This tolerogenic effect has not been described in 
MHC-mismatched grafts and thus the role of C3 in tolerance currently remains 
unclear. 
 
2.4 Complement and renal fibrosis 
C3 synthesis by renal epithelial cells has been reported to mediate proteinuria 
induced tubular damage and activate the renin-angiotensin-aldosterone system with 
a possible role in epithelial to mesenchymal transition [100, 101].  C3 knockout 
kidney allografts transplanted to wild-type were protected from proteinuria, toxin 
induced tubular damage and loss of renal function despite circulating C3 levels [102].  
Activation of C3 from intrinsic renal cells could therefore contribute to the fibrosis 
seen in allograft failure in chronic rejection with donor derived C3 potentially playing 
an important role in its development.  
 
2.5 Complement and the coagulation system 
Both of these pathways are serine protease cascades with interlinking molecules, for 
example, C5a and C5b-C9 increasing tissue factor production from endothelial cells 
(ECs) leading to stimulation of the coagulation system and release of thrombin from 
pro-thrombin [103].  The lectin pathway enzyme MASP-2, can also cleave pro-
thrombin to thrombin and activate fibrinolysis [104].  Thrombin, Factors XIa, Xa, IXa 
and plasmin are all described to cleave C3 and C5 showing how these pathways 
interlink and may initiate complement activation independently of established 
pathways [105].  The binding of alloantibodies to the donor organ endothelium 
triggers complement and coagulation cascades in a pro-inflammatory and pro-
coagulant response mediated by C5a and C5b-C9.  The EC response is variable 
causing immediate thrombosis and infarction of the graft or a lesser injurious 
process, in the presence of alloantibodies and complement. 
 
ECs express CD46 and CD55 that inhibit the cleavage of C3 and C5 by the 
converting enzymes of the classical and alternative pathways.  They also express 
CD59 that blocks the insertion of C5b-C9 into the cell membrane.  In cardiac and 
renal transplants accommodation has been reported to arise from increased 
expression of these inhibitors in the allograft [106, 107].  Accommodation is defined 
as an acquired resistance of an organ to immune mediated damage thereby 
maintaining good allograft function [108].  Cultured human ECs upregulate CD55 
and CD59 when stimulated with pathogenic antibodies, C5b-C9, thrombin and other 
pro-inflammatory molecules such as TNF [109, 110].  Other studies suggest anti-
apoptotic proteins such as BCL-2 and haem oxygenase 1 (HO1) upregulate CD55 
thereby enhancing endothelial resistance and promoting accommodation of the graft 
[111].  ECs also modulate T cell function and expansion through local production of 
complement and CD88 signalling on T cells seen in heart and kidney transplantation 
models [112, 113].  In view of this, manipulation of complement regulators may prove 
an effective treatment strategy in the treatment of antibody-mediated rejection. 
 
3. New therapeutic targets 
Appreciation of the relative roles of the peripheral and central complement 
production play in the development of IR/DGF, cell mediated rejection, AMR, CAMR, 
tolerance or renal fibrosis allows new therapeutics to be developed accordingly.  This 
will also depend on the particular complement components being targeted.  
 
3.1 Target - Donor organ derived complement 
A number of methods are being developed on the basis of animal studies that one 
day may lead to modification of a donor organ to protect it from inflammatory or 
immunological injury that is initiated upon contact with recipient blood.  A summary of 
new therapeutics are described in Table 2. 
 
3.1.1 Small interfering RNAs (siRNAs)  
siRNAs are double stranded RNA that are manipulated to selectively silence the 
gene expression of the target such as C3 or CD88 thereby protecting against post-
ischaemic acute kidney injury [114]. They may also be introduced directly to the 
donor organ in preservation fluid prior to transplantation previously described in a 
murine model [35, 115, 116]. This approach has also used antisense 
oligonucleotides [116] however, high concentrations of this agent are required to 
induce an effect. 
 
3.1.2 Complement regulatory proteins 
Complement regulatory proteins that remain in the donor organ following 
transplantation may act as potential therapeutic targets, however this is limited by an 
inability to upregulate these factors and directly deliver these agents to the target 
organ [117].  An analogue of human complement regulatory protein CD35 has been 
developed that destabilises the C3 and C5 convertases affecting all complement 
pathways.  In this molecule, a basic peptide with the ability to bind acidic 
phospholipid headgroups is combined with a myristoyl fatty acid group (Mirococept, 
APT070) allowing the active fragment of CD35 to attach to the outer leaflet of the cell 
membrane lipid bilayer.  It is maintained there through electrostatic interactions at 
the cell membrane with the peptide amino groups.  This enables the complement 
regulator to function locally.  Previous studies have shown Mirococept to localise to 
endothelial and epithelial cell surfaces once infused through the renal artery in rat 
and human donor kidneys [118, 119].  This resulted in a decrease in IR injury and 
less chronic vascular injury in rat donor organs.  A clinical trial is currently underway 
to determine its efficacy in the prevention of IR injury in transplanted kidneys 
(EMPIRIKAL) [120]. The modification used with this CD35 fragment, known as 
“cytotopic” and has also been applied to other complement regulatory proteins such 
as CD59 and CD55. 
 
3.2 Target – Systemic complement 
Eculizumab is a C5-specific antibody licensed for use in patients with paroxysmal 
nocturnal haemoglobinuria and aHUS [121, 122].  This antibody inhibits the 
formation of C5a and C5b-C9 and therefore can prevent the pore formation on the 
transplant endothelium [123].  Eculizumab has been shown to be effective in the 
prevention of AMR, in the reversal of established rejection and in the recurrence of 
aHUS in the kidney allograft [123-125].  Factor H synthesised in the liver and CD46, 
a transmembrane protein, are the commonest mutations found in aHUS that result in 
intrarenal thrombosis and haemolysis as the complement pathways are largely 
unregulated post-transplant.  Eculizumab has been revolutionary in these patients 
allowing successful transplantation in this cohort of patients [125-128].  Eculizumab 
is also being tested for the prevention of delayed graft function (NCT01403389). 
 
Murine studies have used a combination of the complement receptor CR2 that 
detects membrane bound active and inactive C3b and C3d, fused to a complement 
regulator CRRY or Factor H thus inhibiting complement activation at the targeted 
site.  The CR2-CRRY combination drug inhibits all the complement pathways, 
whereas CR2-Factor H targets the alternative pathway, however both reduce post-
ischaemic myocardial damage [129].  CR2-CRRY inhibition has also been described 
to reduce IR injury in cardiac transplants in recipients from deceased and live donors 
[130].  Recombinant human C1q antagonists have been tested in acute AMR in 
baboons and provide alternative targets in humans to block the early activation of 
complement [131]. 
 
A C3 antagonist – Yunnan-cobra venom factor (Y-CVF) given to HLA-sensitised 
rhesus monkeys following a HLA incompatible kidney transplant, maintained normal 
renal function.  They had low levels of DSA and variable low level C4d deposition on 
biopsy up to 100 days later.  In contrast, the non-treatment group developed early 
AMR and lost their grafts.  It is unclear whether this can be extrapolated to human 
complement in view of species difference however it appeared proximal complement 
blockade may induce accommodation with grafts being preserved despite high levels 
of antibody [132]. 
 
Pexelizumab (Pex), is a recombinant short acting single chain variable fragment 
derivative of Eculizumab.  Pex was being studied in a clinical phase III trial in 
patients with myocardial infarction with primary percutaneous coronary intervention 
or coronary artery bypass [133]. No difference in 30-day mortality was observed 
between treated and untreated patients and thus no further clinical trials have been 
undertaken.  In addition, a neutralising C5 antibody utilizing a different epitope to 
Eculizumab has also been developed known as ‘Mubodina’ however sepsis and the 
development of inflammatory disease are side effects that have limited clinical trials 
[134].  In contrast, Compstatin is a cyclic tridecapeptide C3 inhibitor function that 
continues to be promising in clinical trials as a treatment for age-related macular 
degeneration [135].  It binds C3 reversibly whilst inhibiting the convertase mediated 
cleavage of C3 to C3a and C3b affecting the classical and alternative pathways. 
 
Recently new anti-complement monoclonal antibodies have entered into clinical 
trials.  Anti-MASP-2 is a human monoclonal antibody that selectively inhibits MASP-2 
thereby blocking the lectin pathway.  There are ongoing clinical trials in aHUS and if 
successful this selective blockade may be associated with a lower infectious risk as 
the classical pathway would remain unaffected [135].  Previous murine models have 
shown a reduction in IR injury of the myocardium and gastrointestinal tract with 
blockade of MASP-2 [51].  Anti-C1s monoclonal antibody has been reported to inhibit 
HLA-antibody induced complement activation [136].  Anti-C1s may be useful in 
modulating effects of DSA by inhibiting complement deposition and split product 
formation arising from HLA class I and II seen in vitro, human clinical trials are 
pending.  Anti-CD88 monoclonal antibody has been reported to dramatically 
decrease joint inflammation in a murine model of arthritis following a single 
treatment.  It is thought to induce its effects by reducing neutrophil infiltration and 
activation whilst modulating circulating T cells [137].  A combination of these agents 
may provide effective therapy in the near future however the challenge of when and 
how long to use them for leads to the question of whether any biomarkers exist that 
may aid this decision making. 
 
4. Biomarkers of effective therapy 
Donor C3 has previously been described to be associated with the risk of graft 
dysfunction [138]. A microarray analysis of complement in donors prior to 
transplantation showed high levels of C3 in organs with a poor allograft function at 3 
years follow up [19].  Poor graft function has also been associated with 
tubuloepithelial complement deposition on pre-implantation biopsies [138].  C4d 
deposition identified on transplant biopsies has been synonymous with AMR [139].  
In addition, serological tests have been developed to determine complement fixing 
HLA-specific antibodies that have been reported to have a higher sensitivity to 
underlying episodes rejection [138].  Detection of serum anti-HLA antibodies binding 
C1q in kidney transplantation have also been associated with poor graft function 
[89].  Currently there continues to be a paucity of good complement biomarkers to 
guide new potential therapies. 
 
MBL levels may also be used as lectin pathway complement biomarkers with higher 
risks of infections reported in those with low MBL expression post liver transplant 
reflecting underlying inactivity of the lectin pathway [140].  In kidney transplants, high 
levels of MBL correlate with aggressive rejection and graft failure [55].  CD55 has 
been reported to be a marker of renal allograft survival when expressed in the 
peritubular capillaritis of AMR [141] that could be used as a biomarker whose 
presence may herald cessation of complement inhibitory treatment.  It is increasingly 
important with the development of complement inhibitory therapies to identify 
biomarkers that may help guide the clinician to determine when treatment should be 
held or restarted.  
 
4.1 Biomarker limitation 
The difficulty in measuring and detecting complement activity within grafts is more 
challenging over time as it remains unclear whether donor derived complement is 
lifelong.  Serial biopsies are not an acceptable risk and are also subject to sampling 
errors thereby limiting their usefulness in the clinical arena.  Imaging techniques may 
track complement activity using conjugated CR2 with superparamagnetic iron oxide 
(SPIO) nanoparticles [142].  Alternatively, CR2 radiolabelled with 99mTc can be 
injected and followed with single-photon emission computer tomography (SPECT) 
imaging allowing real-time visualisation of post-ischaemic myocardial injury that may 
further elucidate the function of major targets [143, 144]. 
 
5 Conclusion 
In order to promote complement inhibition there needs to be a deeper understanding 
of the dual function of complement to promote and limit tissue damage whilst 
regulating T cell function that may help induce a tolerant state [99, 145].  
Determining which triggers initiate the complement cascade in transplantation will 
provide new targets specific to the dominant complement pathway activated that 
may be inhibited to prevent allograft loss.  The Lectin pathway is increasingly 
described in kidney transplantation and may allow new ligands on injured tissue 
causing this activation to be identified and subsequently targeted with new 
therapeutics.  Complement inhibition continues to pose a theoretical risk of infection 
as a number of human complement regulators are receptors for human pathogens, 
thus a careful balance needs to be achieved between benefit versus harm.  
Complement genotyping before transplantation may also be a helpful adjunct to 
stratify risk. In future we may also see effective ways of treating the donor graft prior 
to transplantation resulting in longer and more effective graft survival. 
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Figures 
Figure 1. The complement cascades. 
The classical pathway is triggered by the C1 complex (C1q, C1r, C1s) binding to 
antibody or C-reactive protein on the activating surface, leading to the formation of 
the classical pathway C3 convertase from C4 and C2 (C4bC2a) and to subsequent 
cleavage of C3.  The lectin pathway is activated by collectins (e.g. Mannose binding 
lectin, MBL) or ficolins that detect carbohydrate residues, IgA or IgM on the 
activating surface. Complexes formed between the lectin molecule and MBL-
associated serine proteases result in the formation of C3 convertase (C4bC2a), as 
per the classical pathway. In contrast the alternative pathway begins with direct 
binding of C3b to the activating surface after spontaneous hydrolysis of C3 or 
following the deposition of C3b by the classical or lectin pathway. In this case, C3b 
binds factor B followed by cleavage of factor B to form the alternative pathway C3 
convertase (C3bBb). All three pathways form enzyme complexes (classical or 
alternative convertases) that cleave C3 into C3a and C3b and ultimately cleave C5 
into C5a and C5b. C5b triggers the terminal pathway forming the membrane attack 
complex (C5b-C9), which creates a pore in the cells membrane resulting in cell lysis 
and death.  Specific cell surface receptors detect C3a, C5a, iC3b, C3b and C3d.  
Complement regulators (CR) include: CD35 (CR1), CD46 (MCP), CD55 (DAF), 
C4BP (C4b-binding protein) and complement Factor H, which function by 
accelerating decay of the C3 and C5 convertases or by acting as cofactors for the 
proteolysis of these convertases by Factor I, or have both of these actions; and 
CD59 (Protectin), which binds C8 and inhibits membrane attack complex formation 
Table 1 provides further details of CR.  
Tables 
 
Table 1 Function of membrane bound and soluble complement regulators and 
whether they are specifically synthesised within the kidney [146] 
Complement regulator Function Synthesised in 
the kidney 
CD55 (Decay 
accelerating factor 
DAF) – membrane 
bound 
Membrane bound complement 
regulator accelerates cell surface 
assembly of C3 convertase 
Yes- 
podocytes/EC/ 
juxtaglomerular 
cells 
CD46 (membrane 
cofactor protein MCP) – 
membrane bound 
Cofactor with Factor I inactivates C3b 
and prevents the formation of C3 
convertase 
Yes- renal tissues 
CD59 (Protectin) –
membrane bound 
Inhibits C9 and MAC formation Yes- all major cell 
types 
CD35 (CR1) –
membrane bound 
Inhibits C3 convertase limiting 
amplification of complement cascade 
and MAC formation. Decay and 
cofactor activities 
Yes –variable 
expression 
FH (Factor H) –soluble Exhibits decay accelerating and 
cofactor activity of alternate pathway 
Yes –tubule cells 
C4BP (C4b binding 
protein) –soluble 
Accelerates the decay of C3 and C5 
convertase and cofactor activity of 
classical pathway 
Podocytes 
CFH related protein-1 Competes with Factor H function with 
controversial studies suggesting 
additional C5 convertase inhibitor 
activity 
No 
FI (Factor I) Regulates degradation of C3b and 
C4b 
Yes –on 
microarray for CFI 
Properdin Stabilises the alternative pathway 
convertases 
Yes – renal 
tissues 
Vitronectin (S-protein) Inhibits C5b-7 and MAC formation 
affecting adhesion proteins, 
fibronectin attachments and 
coagulation pathway. 
Unknown –
accumulates in 
glomeruli 
CRIg (VSIG4) Inhibits C3 on macrophages affecting 
phagocytosis and alternative pathway 
activation 
Unknown 
 
 
 
Table 2 New therapeutic agents directly or indirectly targeting components of the 
complement system in the classical, alternative, and lectin pathways. 
 
Agent Target Studies 
Recombinant human C1q 
inhibitor 
C1q Animal AMR 
Anti-C1s monoclonal 
antibody (True North) 
C1s Animal inhibits complement activation from 
HLA Antibodies potential AMR treatment. 
Human clinical trial commencing. 
Anti-MASP-2 monoclonal 
antibody (Omeros) 
MASP-2 Animal –reduction in myocardial and 
gastrointestinal IR. Human clinical trial 
Mirococept (APT070) 
CD35 (CR1) inhibitor 
CD35 Rodent and pig animal studies, human 
(Phase 1 and Phase 2 trial) 
Compstatin C3 inhibitor C3 Human clinical trial –Age-related macular 
degeneration 
Small interfering RNAs 
(siRNAs) 
C3 or 
CD88 
Animal model IR injury (84,85) 
Eculizumab (anti-C5 
antibody) 
C5 ABOi/HLAi transplants 
Delayed graft function 
Anti-CD88 monoclonal 
antibody 
CD88 Animal –reduction in arthritis. Human 
clinical trial 
CR2-CRRY, CR2- Factor 
H 
CR2 Animal post-ischaemic myocardial damage 
 
